Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(3.06)
# 2,591
Out of 5,180 analysts
53
Total ratings
42.86%
Success rate
14.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Initiates: Overweight | n/a | $3.94 | - | 1 | Dec 18, 2025 | |
| NVAX Novavax | Initiates: Overweight | $18 | $8.14 | +121.13% | 1 | Oct 24, 2025 | |
| ALEC Alector | Downgrades: Neutral | n/a | $2.15 | - | 6 | Oct 22, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $0.88 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $72.97 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $40.23 | +148.57% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $3.86 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $7.72 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.26 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $20.13 | - | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.54 | - | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.30 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $83.92 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.05 | +63.93% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.36 | +450.85% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $21.87 | -63.42% | 1 | Mar 20, 2023 |
CervoMed
Dec 18, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.94
Upside: -
Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $8.14
Upside: +121.13%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.15
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.88
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $72.97
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $40.23
Upside: +148.57%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.86
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.72
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.26
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.13
Upside: -
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.54
Upside: -
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.30
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $83.92
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $3.05
Upside: +63.93%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $2.36
Upside: +450.85%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $21.87
Upside: -63.42%